Griazeva Ekaterina D, Fedoseeva Daria M, Radion Elizaveta I, Ershov Pavel V, Meshkov Ivan O, Semyanihina Alexandra V, Makarova Anna S, Makarov Valentin V, Yudin Vladimir S, Keskinov Anton A, Kraevoy Sergey A
Federal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Pogodinskaya Str., 10, Building 1, Moscow 119121, Russia.
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Kashirskoe Shosse, 24, Moscow 115478, Russia.
Epigenomes. 2023 Sep 30;7(4):23. doi: 10.3390/epigenomes7040023.
Epigenetic therapy is a promising tool for the treatment of a wide range of diseases. Several fundamental epigenetic approaches have been proposed. Firstly, the use of small molecules as epigenetic effectors, as the most developed pharmacological method, has contributed to the introduction of a number of drugs into clinical practice. Secondly, various innovative epigenetic approaches based on dCas9 and the use of small non-coding RNAs as therapeutic agents are also under extensive research. In this review, we present the current state of research in the field of epigenetic therapy, considering the prospects for its application and possible limitations.
表观遗传疗法是治疗多种疾病的一种有前景的工具。已经提出了几种基本的表观遗传方法。首先,作为最成熟的药理学方法,使用小分子作为表观遗传效应物促使多种药物进入临床实践。其次,基于dCas9以及使用小非编码RNA作为治疗剂的各种创新表观遗传方法也在广泛研究中。在这篇综述中,我们介绍了表观遗传疗法领域的当前研究现状,同时考虑其应用前景和可能的局限性。